Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Lauren C Shapiro; Astha Thakkar; Sean T Campbell; Stefanie K Forest; Kith Pradhan; Jesus D Gonzalez-Lugo; Ryann Quinn; Tushar D Bhagat; Gaurav S Choudhary; Margaret McCort; R Alejandro Sica; Mendel Goldfinger; Swati Goel; Jesus D Anampa; David Levitz; Ariel Fromowitz; Akash Pradip Shah; Charlotte Sklow; Gregory Alfieri; Andrew Racine; Lucia Wolgast; Lee Greenberger; Amit Verma; Balazs Halmos

doi:10.1016/j.ccell.2021.11.006

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Cancer Cell. 2022 Jan 10;40(1):3-5. doi: 10.1016/j.ccell.2021.11.006. Epub 2021 Nov 16.

Authors

Lauren C Shapiro¹, Astha Thakkar¹, Sean T Campbell², Stefanie K Forest², Kith Pradhan¹, Jesus D Gonzalez-Lugo¹, Ryann Quinn¹, Tushar D Bhagat¹, Gaurav S Choudhary¹, Margaret McCort³, R Alejandro Sica¹, Mendel Goldfinger¹, Swati Goel¹, Jesus D Anampa¹, David Levitz¹, Ariel Fromowitz¹, Akash Pradip Shah¹, Charlotte Sklow¹, Gregory Alfieri¹, Andrew Racine⁴, Lucia Wolgast², Lee Greenberger⁵, Amit Verma⁶, Balazs Halmos⁷

Affiliations

¹ Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
² Department of Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
³ Division of Infectious Diseases, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
⁴ Department of Pediatrics, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA.
⁵ The Leukemia & Lymphoma Society, Rye Brook, NY, USA.
⁶ Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: [email protected].
⁷ Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: [email protected].

Abstract

Anti-COVID-19 immunity dynamics were assessed in patients with cancer in a prospective clinical trial. Waning of immunity was detected 4-6 months post-vaccination with significant increases in anti-spike IgG titers after booster dosing, and 56% of seronegative patients seroconverted post-booster vaccination. Prior anti-CD20/BTK inhibitor therapy was associated with reduced vaccine efficacy.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors
Antibodies, Viral / biosynthesis*
Antibodies, Viral / blood
Antibodies, Viral / immunology
Antigens, Viral / immunology
COVID-19 / complications
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Follow-Up Studies
Humans
Immunization, Secondary*
Immunocompromised Host
Immunogenicity, Vaccine
Immunoglobulin G / biosynthesis*
Immunoglobulin G / blood
Immunoglobulin G / immunology
Neoplasms / complications
Neoplasms / drug therapy
Neoplasms / immunology*
Prospective Studies
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Rituximab / adverse effects
Rituximab / therapeutic use
SARS-CoV-2 / immunology*
Seroconversion
Spike Glycoprotein, Coronavirus / immunology
Vaccination

Substances

Antibodies, Viral
Antigens, Viral
COVID-19 Vaccines
Immunoglobulin G
Protein Kinase Inhibitors
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Rituximab
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human

Abstract

Publication types

MeSH terms

Substances

Grants and funding